AstraZeneca Highlights Results from the P-III (DUO-E) Study Evaluating Imfinzi for the Treatment of Endometrial Cancer at SGO 2024
Shots:
- The 3-armed P-III (DUO-E) study assesses 1L Imfinzi (durvalumab) + CT (carboplatin & paclitaxel) followed by either Imfinzi monotx. or Imfinzi + Lynparza (olaparib) as maintenance therapy, Imfinzi + CT followed by Imfinzi alone vs CT alone for treating newly diagnosed advanced/recurrent endometrial cancer patients (n=699)
- The post-hoc analysis in the pMMR population showed more than double mDoR of 18.7mos. vs 7.6mos. & reduced risk in PFS2 by 32% with the combination vs control arm (median not attained vs 19.5mos.) as well as improvement in time to 1st & 2nd subsequent treatments
- In the dMMR population across the Imfinzi arm, the ORR was 71.4% with mDoR not attained vs the control arm (40.5%mos. & 10.5mos., respectively)
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports the Results for the Combination of Imfinzi, TACE, and Bevacizumab in P-III Trial for Hepatocellular Carcinoma (HCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
